Aster DM Quality Care Q1FY27 Revenue up 22% to ₹1,311 Cr, EBITDA up 29% to ₹277 Cr
Aster DM Quality Care reported Q1FY27 revenue of ₹1,311 Cr, up 22% YoY. Operating EBITDA grew 29% to ₹277 Cr, with margins improving to 21.1%. Normalised PAT increased 39% to ₹125 Cr. The combined entity posted Q1FY27 revenue of ₹2,597 Cr (up 20%) and EBITDA of ₹576 Cr (up 30%).
The announcement details strong financial results for the quarter and highlights the successful integration post-merger, which is a significant event for the company's future growth and profitability.
The company reported strong year-on-year growth in revenue and EBITDA, along with improved margins and PAT, indicating positive financial performance.
Aster DM Quality Care Limited announced its financial results for the quarter ended June 30, 2026 (Q1FY27), reporting a significant year-on-year growth. Revenue from operations increased by 22% to ₹1,311 crore, driven by higher patient volumes, improved realizations, a stronger specialty and payor mix, doctor additions, and the ramp-up of the Kasargod facility.
The company's Operating EBITDA saw a robust 29% YoY growth, reaching ₹277 crore. This was supported by strong revenue growth, operating leverage, and disciplined cost management. The Operating EBITDA margin improved by 117 basis points to 21.1%. Normalised Profit After Tax (PAT) post non-controlling interest grew by 39% to ₹125 crore.
The merger with Quality Care became effective on July 1, 2026, forming Aster DM Quality Care Limited. The combined entity demonstrated strong proforma performance in Q1FY27, with revenue reaching ₹2,597 crore, a 20% YoY growth, and Operating EBITDA growing by 30% YoY to ₹576 crore. The EBITDA margin for the combined entity was 22.2%.
Key operational highlights include a 13% YoY growth in total patient volume and a 10% YoY increase in Average Realization Per Patient (ARPP) IP. Medical Value Travel (MVT) grew by 62% for the combined entity. The company also reported significant improvements in clinical metrics, with robotic surgeries up 80%, bone-marrow transplants up 80%, kidney transplants up 55%, and joint replacements up 27% year-on-year.
The company presented an investor presentation for the quarter ended June 30, 2026, in relation to the unaudited financial results. This presentation was shared in anticipation of the Earnings Conference Call scheduled for August 5, 2026.
What to do with a filing like this
Aster DM Quality Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Quality Care Limited. Read the original for the full detail.